Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Cheng, Qing ^a   Lu, Li ^a,b   Grafström, Jonas ^a   Olofsson, Maria Hägg ^a   Thorell, Jan Olov ^a,b   Samén, Erik ^a,b   Johansson, Katarina ^a   Ahlzén, Hanna Stina ^a   Stone Elander, Sharon ^a,b   Linder, Stig ^a   Arnér, Elias S J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE CLEAVED CYTOKERATIN 18; CYTOKERATIN 18; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SEL TAGGED LIPOCORTIN 5 C 11; UNCLASSIFIED DRUG; CARBON; LIPOCORTIN 5; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TISSUE METABOLISM; TISSUE SECTION; TUMOR XENOGRAFT; VALIDATION PROCESS; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; DISEASE MODEL; METABOLISM; METHODOLOGY; MOUSE MUTANT; RADIOGRAPHY; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ANIMALIA; MUS;

ANIMALS; ANNEXIN A5; APOPTOSIS; CARBON ISOTOPES; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864752361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042151     Document Type: Article

References (29)

1. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS, (2011) Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8: 135-141.
2. Blankenberg FG, (2009) Apoptosis imaging: anti-cancer agents in medicinal chemistry. Anticancer Agents Med Chem 9: 944-951.
3. Blankenberg FG, (2009) Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V. Proc Am Thorac Soc 6: 469-476.
4. Blankenberg FG, (2009) Apoptosis Imaging: Anti-Cancer Agents in Medicinal Chemistry. Anticancer Agents Med Chem.
5. Blankenberg FG, (2008) In vivo imaging of apoptosis. Cancer Biol Ther 7: 1525-1532.
6. Decuzzi P, Pasqualini R, Arap W, Ferrari M, (2009) Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26: 235-243.
7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
8. Cheng Q, Stone-Elander S, Arnér ESJ, (2006) Tagging recombinant proteins with a Sel-tag for purification, labeling with electrophilic compounds or radiolabeling with carbon-11. Nat Protocols 1: 604-613.
9. Johansson L, Chen C, Thorell J-O, Fredriksson A, Stone-Elander S, et al. (2004) Exploiting the 21st amino acid- purifying and labeling proteins by selenolate targeting. Nat Methods 1: 61-66.
10. Dierckx RA, Van de Wiele C, (2008) FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35: 1544-1549.
11. Ben-Haim S, Ell P, (2009) 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 50: 88-99.
12. Linder S, Havelka AM, Ueno T, Shoshan MC, (2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214: 1-9.
13. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, et al. (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756.
14. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S, (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94: 1592-1598.
15. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, et al. (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: 3198-3206.
16. Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, et al. (2011) Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer 104: 719-725.
17. Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, et al. (2009) Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark 5: 117-125.
18. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, et al. (2002) Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8: 2766-2774.
19. Blankenberg FG, (2008) In vivo detection of apoptosis. J Nucl Med 49 (Suppl 2): 81S-95S.
20. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, et al. (2000) Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60: 6950-6957.
21. Cheng Q, Johansson L, Thorell J-O, Fredriksson A, Samén E, et al. (2006) Selenolthiol and dithiol C-terminal tetrapeptide motifs for one-step purification and labeling of recombinant proteins produced in E. coli. ChemBioChem 7: 1976-1981.
22. Arnér ESJ, Sarioglu H, Lottspeich F, Holmgren A, Böck A, (1999) High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J Mol Biol 292: 1003-1016.
23. Reichelt P, Schwarz C, Donzeau M, (2006) Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 46: 483-488.
24. Larsen P, Ulin J, Dahlström K, Jensen M, (1997) Synthesis of [11C]iodomethane by iodination of [11C]methane. Appl Radiat Isot 48: 153-157.
25. Samen E, Thorell JO, Lu L, Tegnebratt T, Holmgren L, et al. (2009) Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imaging 36: 1283-1295.
26. Logan J, Alexoff D, Fowler JS, (2011) The use of alternative forms of graphical analysis to balance bias and precision in PET images. J Cereb Blood Flow Metab 31: 535-546.
27. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
28. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, et al. (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
29. Wolf MB, Baynes JW, (2006) The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 1760: 267-271.